Germline Whole-Gene Deletion of SDHA in a Carotid Body Paraganglioma Identified by Whole-Genome Sequencing and Confirmed by MLPA: A Case Report and Review of the Literature
This case report describes the first identification of a germline whole-gene deletion of *SDHA* in a carotid body paraganglioma using whole-genome sequencing and MLPA, demonstrating the critical necessity of these advanced methods to detect elusive structural variants that standard exome-based workflows often miss.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Deep within the neck, where the main artery to the brain splits into two, sits a tiny, specialized cluster of cells known as the carotid body. Its job is to act as a sensor, constantly monitoring the oxygen levels in the blood and signaling the body to breathe faster if the air runs thin. Occasionally, a tumor can grow from these cells. While most are benign, some can be aggressive or spread to other parts of the body. For decades, doctors have known that many of these tumors are driven by errors in a specific set of genes called SDH. These genes act like a cellular engine, helping cells generate energy. When they break, the cell's metabolism goes haywire, and a tumor can form. However, finding the exact broken piece has been a frustrating puzzle. Standard genetic tests are excellent at spotting small typos in the genetic code, but they often miss massive structural errors, such as an entire gene going missing. This blind spot means some patients with a hereditary risk are told they are safe when they are not, leaving them without the careful monitoring they need.
A team of researchers at Keio University School of Medicine and the Cancer Institute Hospital of the Japanese Foundation for Cancer Research recently solved one of these missing pieces. They followed the story of a sixty-three-year-old woman who came to their clinic with a slow-growing, painless lump on the left side of her neck. She had no family history of similar tumors, which usually suggests the condition appeared by chance rather than being inherited. Imaging confirmed the mass was a tumor sitting right at the carotid artery split, and surgeons successfully removed it. When pathologists examined the tissue under a microscope, they saw the classic signs of a paraganglioma. More importantly, they used a special staining technique to look for the proteins produced by the SDH genes. The tumor cells were completely missing two of these proteins, a strong clue that the SDHA gene was the culprit.
Yet, when the team ran standard genetic tests on the woman's blood, they found nothing. The usual methods, which scan the DNA for small errors, came up empty. This is a common dead end for SDHA because the gene sits in a crowded neighborhood of nearly identical genetic copies that confuse the testing machinery. Undeterred, the researchers turned to a more powerful tool called whole-genome sequencing. Instead of just looking at the small, coding parts of the DNA, this method reads the entire genetic landscape, including the vast spaces between genes. This broad view revealed the truth: the woman had inherited a deletion of the entire SDHA gene from one of her parents. It was as if a whole chapter had been ripped out of her genetic instruction manual. The copy number analysis showed she had only one working copy of this gene instead of the usual two.
To confirm this finding, the team analyzed the removed tumor tissue itself. They discovered that the tumor had lost the remaining healthy copy of the gene, leaving the cells with no functional SDHA at all. This confirmed a long-standing theory in cancer biology known as the "two-hit" hypothesis, where a person inherits one broken gene and then loses the second good one in a specific tissue, triggering the disease. The researchers double-checked their work using a different laboratory technique called multiplex ligation-dependent probe amplification, which acts like a precise measuring tape for DNA. This test confirmed that the entire gene was indeed missing in the patient's blood and that the tumor had lost the last remaining piece. This case represents the first time a whole-gene deletion of SDHA has been identified in a carotid body tumor using this comprehensive sequencing approach.
The implications of this discovery extend far beyond this single patient. Because standard tests often miss these large deletions, many people with this specific genetic risk might be overlooked. The researchers note that while tumors linked to SDHA are rare, they carry a significant risk of becoming malignant and spreading to distant parts of the body. Identifying the true cause is vital for the patient's future care, as it dictates a rigorous schedule of imaging to catch any recurrence early. It also changes the story for her family. Even though she had no relatives with the disease, the presence of this inherited deletion means her children and siblings could carry the same risk. By using whole-genome sequencing to find what standard tests missed, the team provided a definitive answer, ensuring the patient receives the correct surveillance and allowing her family to understand their own health risks. This case serves as a reminder that in the complex world of genetics, sometimes the most important clues are the ones that are too large to be seen by the usual methods.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.